CD19 and hematologic disorder: Based on the success of CD19-targeted CAR-T cells (36), approved by U.S. Food and Drug Administration (FDA), the first CAR-NK cells were engineered with chimeric anti-CD19 single chain fragment variable (scFv) for the cure of hematologic malignancies (21).